Cost-utility analysis of 1- and 2-level dorsal lumbar fusions with and without recombinant human bone morphogenic protein-2 at 1-year follow-up

Medicine & Life Sciences

• Quality-Adjusted Life Years 100%
• Autografts 98%
• Cost-Benefit Analysis 78%
• Costs and Cost Analysis 56%
• Bone and Bones 53%
• Ilium 44%
• Proteins 33%
• Transplants 24%
• Patient Health Questionnaire 16%
• Cost Control 16%
• Medicare 13%
• Pain Measurement 12%
• Risk Assessment 10%
• Income 10%
• Control Groups 6%
• Health 6%